|
![]() |
RequipThis page contains recent news articles, when available, and an overview of Requip but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Requip (when available) Ropinirole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The mechanism of ropinirole-induced postural hypotension is presumed to be due to a D2 -mediated blunting of the noradrenergic response to standing and subsequent decrease in peripheral vascular resistance. For the treatment of the signs and symptoms of idiopathic Parkinson's disease. Also used for the treatment of restless legs syndrome. Mechanism Of Action: Ropinirole binds the dopamine receptors D3 and D2. Although the precise mechanism of action of ropinirole as a treatment for Parkinson's disease is unknown, it is believed to be related to its ability to stimulate these receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that ropinirole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum. News Articles on Ropinirole Requip: "Will My Family Ever Forgive Me?" - Apr 4, 2009 Bensalem, PA: "When I found out Requip is to blame for my gambling I was relieved that I wasn't a bad person but I don't think my family will ever forgive Lawyers and Settlements XenoPort Announces Election of Co-Promotion Option for Solzira™ - Apr 13, 2009 XenoPort also announced changes to the terms of its right to co-detail in the US Requip® XL™, GSK's product for Parkinson's disease. Business Wire (press release) Requip Breaks Up Marriage - Mar 30, 2009 Tampa, FL: Kathy started taking Requip in 2005 for Restless Leg Syndrome and it did help her sleep at night, but she would have sacrificed many a good Lawyers and Settlements Parkinson’s Drugs Side Effects linked to Compulsive Gambling and Sex - Apr 14, 2009 The class of drugs include medications such as Requip (ropinirole), Mirapex (pramipexole), Dostinex (cabergoline), Parlodel (bromocriptine), AboutLawsuits.com Report: Pfizer, Boehringer Ingelheim, Bayer Favored in Wisconsin's ... - Mar 30, 2009 The online courses were in antismoking (Pfizer/Chantix), restless legs syndrome (Boehringer/Mirapex and GSK/Requip), and PMS (Bayer/Yaz). BNET HIRE ME: Mara Feldman - Apr 3, 2009 Senior neuroscience pharmaceutical consultant who promoted Paxil and Requip to hospitals and psychiatrists in Morris and Passaic counties. The Star-Ledger - NJ.com Glaxo's Avandia Issue Priced-In - Apr 8, 2009 Glaxo still has to deal with generic erosion of a number of drugs, including Coreg IR, Flonase, Wellbutrin XR, Lamictal, Requip, Valtrex and Imitrex. Zacks.com Drug firms' cash skews doctor classes - Mar 29, 2009 The other drug mentioned in the course as a first choice therapy is Requip, made by GlaxoSmithKline. The company also provided funding to two outside TMCnet I don't see Prabhakaran as a terrorist, says Karunanidhi - Apr 19, 2009 Each and everytime the LTTE took advantage of the lull in the operations to requip themselves to continue the terrorist attach on their own tamil and MSN India Research Oracle roundup for 07 April 2009 - Apr 7, 2009 ...such as Coreg, Imitrex, Lamictal, Paxil, Requip, Wellburtin and Zofran, coupled with decline in sales for its anti-diabetic drug, Avandia. Research Oracle GlaxoSmithKline PLC (NYSE:GSK) - Vaccines and Respiratory products ... - Apr 7, 2009 ...such as Coreg, Imitrex, Lamictal, Paxil, Requip, Wellburtin and Zofran, coupled with decline in sales for its anti-diabetic drug, Avandia. Research Oracle Restless Legs Syndrome tied to obesity, fat waistlines - Apr 7, 2009 Doctors prescribe dopamine agonists like Requip or Mirapex, which can have side effects, like daytime sleepiness, nausea and drop in blood pressure. 6abc.com Zacks Analyst Blog Highlights: GlaxoSmithKline plc, General Growth ... - Apr 9, 2009 Glaxo still has to deal with generic erosion of a number of drugs, including Coreg IR, Flonase, Wellbutrin XR, Lamictal, Requip, Valtrex and Imitrex. PR-Inside.com (Pressemitteilung) Parkinson: addictions associées à certains médicaments - Apr 8, 2009 ...les agonistes de la dopamine (ou agonistes dopaminergiques) (1), inclut le pramipexole (Sifrol ou Mirapex) et le ropinirole (Requip). PsychoMédia Requip Users and Financial Losers - Mar 11, 2009 Atlanta, GA: "I would like to say to the manufacturers of Requip that in this economy, it is hard enough to make a living and keep a roof over your head Lawyers and Settlements Requip User Wants to Recoup Casino Losses - Mar 10, 2009 Memphis, TN: Sonny's doctor first prescribed Requip about 6 years ago and he took anywhere from 4-6 pills a day for Parkinson's Disease. Lawyers and Settlements "Requip Maker should Pay Back My Gambling Losses" - Mar 1, 2009 That is, until she took Requip and lost her life savings. " I really want the manufacturer to warn consumers of Requip compulsive gambling, so everyone who Lawyers and Settlements Research and Markets: Requip Case Study: Life Cycle Management ... - Mar 9, 2009 This case study reviews the strategy and tactics utilized by GlaxoSmithKline for the Parkinson's indicated product, Requip/Adartrel, to manage the life and Business Wire (press release) Restless leg syndrome kicks up during night - Feb 21, 2009 My doctor is afraid to give me Requip because I take so much Ativan. My legs are driving me crazy. I started taking 6 ounces of tonic water at night. South Coast Today Teva's Azilect Use Dramatically Increases in Second-Line Therapy ... - Mar 4, 2009 ...of levodopa/carbidopa and non-ergotic dopamine agonists, which include Boehringer Ingelheim's Mirapex and GlaxoSmithKline's Requip/Requip XL, generics. PR Newswire (press release) Generics Will Challenge Parkinson's Drug Sales in 2010, According ... - Feb 21, 2009 GlaxoSmithKline's Requip XL, for example, is the second highest-selling dopamine agonist. "Generic competition from Barr may easily hurt Requip sales, PR-USA.net (press release) Long-term results similar in two Parkinson's drugs - Mar 9, 2009 N) Requip, or ropinirole. The researchers tracked 222 patients in the study published in the journal Archives of Neurology. Of those who started on Mirapex, Reuters Des milliers de patients traités au Mirapex sont accros au jeu - Mar 7, 2009 ...les patients atteints de la maladie de Parkinson et traités avec un substitut de la dopamine, comme le Mirapex et le Requip, son principal concurrent. La Presse Expertos dicen que el principal reto contra el Parkinson es tratar ... - Feb 20, 2009 ...comercializado como 'Requip' por GSK, que con una única dosis logra mejorar la calidad de vida del paciente, según el Estudio Prepared. ecodiario Requip Complaints and Cases - Jan 22, 2009 Philadelphia, PA: Requip, the popular drug prescribed to control tremors for sufferers with Parkinson's Disease and Restless Leg Syndrome, Lawyers and Settlements An assortment of drugs can be taken to treat RLS - Feb 1, 2009 I have taken Lorazepam for it and have tried Requip but couldn't take it because it made me sick. What are the names of the generics you have had good luck Hattiesburg American, Hooked on games of chance - Jan 29, 2009 ...linked those who suddenly became pathological gamblers was traced to medications (Mirapex and Requip) that boosted their brain levels of dopamine. Cleveland Jewish News, Pharma giants have bitter pill after Pfizer deal - Jan 24, 2009 ...best-selling medicines – Lamictal for epilepsy, the antidepressant Wellbutrin XL, Coreg for high blood pressure and Requip for restless legs syndrome. Telegraph.co.uk, What treatments work for Parkinson's disease? - Jan 21, 2009 Some examples of dopamine agonists (and their brand names) are cabergoline (Dostinex), ropinirole (Requip) and pramipexole (Mirapexin). More. guardian.co.uk, Happy Feet Syndrome has nothing in common with RLS - Jan 11, 2009 Two drugs, Mirapex and Requip, have received official FDA indications for the treatment of RLS. They both work fine but are pricey insurance-coverage drugs Hattiesburg American, Trevena, Inc. announces Scientific Advisory Board - Jan 11, 2009 MI and hypertension, dobutamine (Dobutrex) for heart failure, ropinerole (Requip) for Parkinson's Disease, and eprosartan (Teveten) for hypertension. PR-Inside.com (Pressemitteilung), „Ich konnte mich gar nicht mehr bewegen“ - Jan 19, 2009 Sie haben geschaut, dass ich das neue Medikament Requip bekomme, das bisher in St. Pölten nicht angewendet wurde.“ Eine gute Therapie seien auch Musik und NÖN Online, What is the cause of my black stool? - Dec 3, 2008 I'm on enalapril, HCTZ, Requip, simvastatin, terazosin, temazepam, propoxyphene, aspirin, fish oil and calcium daily. What is causing the problem? GoErie.com, Research and Markets: Study Analysis of the RLS Market IMS Sales ... - Dec 17, 2008 Through Requip (ropinirole) and Mirapex's (pramipexole) regulatory approvals in 2005-06, GlaxoSmithKline and Boehringer Ingelheim pioneered the on-label RLS MarketWatch December 2008 Mayo Clinic Health Letter Highlights: Colorectal ... - Dec 9, 2008 ...a sleep aid -- Depakote (divalproex) for seizures, migraines and bipolar disorder -- Fosamax (alendronate) for osteoporosis -- Requip (ropinirole) for MarketWatch Sleep Disorders Market Analysis 2008-2018 - companiesandmarkets ... - Dec 16, 2008 Requip (ropinirole) became the first and only FDA-approved drug treatment for moderate to severe primary Restless Legs Syndrome (RLS) in 2005. Live-PR.com (Pressemitteilung), Parkinson’s Disease Market analysis and forecasts, 2008-2012, 2017 ... - Dec 16, 2008 The leading therapeutics expected to change the PD market dynamics will include, GlaxoSmithKline´s (GSK´s) Requip Once-daily ER awaiting approval, Live-PR.com (Pressemitteilung), Empresas.- 'Requip-Prolib' (GSK) permite un control motor continuo ... - Dec 3, 2008 La liberación prolongada de ropinirol, comercializado por GlaxoSmithKline como 'Requip-Prolib', permite un control motor continuo del paciente con Parkinson ecodiario, Drugmaker GSK to cut back US sales force - Nov 5, 2008 GSK, the maker of antidepressant Wellbutrin and Requip for Parkinson's disease and restless legs syndrome, has about 8500 sales reps among its US staff of Minneapolis Star Tribune, Pipeline and Commercial Insight - Parkinson's Disease - Market to ... - Nov 17, 2008 GSK´s Requip Modutab will become the market leading PD brand in 2011. It will be intuitive for prescribers to believe that sustained activation of dopamine Live-PR.com (Pressemitteilung), Skyepharma announces Interim Management Statement - Oct 29, 2008 Requip® Once-a-day has now been launched in the United States (as Requip® XL) and most European countries. Sales in Q3 2008 were GBP15m. PR-CANADA.net (press release), Consumer Advertising Spend Drops as New Drugs Dwindle - Nov 18, 2008 For example, Requip, which was approved for Parkinson’s in the ‘90s was recently was approved for restless leg syndrome. Since many years have past sine the PharmExec.com, Brain Teasers - Nov 13, 2008 Requip and Mirapex are newer medications, which are safer and more effective than the older drugs, Parlodel and Permax. Symmetrel, anticholinergics (artane Express Healthcare Management, Astellas Halts Phase II of XenoPort Pain Drug - Nov 6, 2008 ...than GSK's currently marketed RLS medication Requip (ropinirole) and Boehringer Ingelheim Pharmaceuticals Inc.'s Mirapex (pramipexole dihydrochloride). BioWorld Online, GlaxoSmithKline plans UK plant closure, job cuts - Nov 11, 2008 GlaxoSmithKline, the maker of antidepressant Wellbutrin and Requip for Parkinson's disease, currently employs around 100000 people worldwide. The Associated Press GlaxoSmithKline trimming US sales force by 1000 - Nov 5, 2008 GlaxoSmithKline, the maker of antidepressant Wellbutrin and Requip for Parkinson's disease and restless legs syndrome, currently has about 8500 US sales The Associated Press GlaxoSmithKline to cut sales force - Nov 8, 2008 GlaxoSmithKline, the maker of antidepressant Wellbutrin and Requip for Parkinson's disease and restless legs syndrome, currently has about 8500 US sales Durham News, GlaxoSmithKline trimming US sales force by 1000 - Nov 5, 2008 GlaxoSmithKline, the maker of antidepressant Wellbutrin and Requip for Parkinson's disease and restless legs syndrome, currently has about 8500 US sales eTaiwan News, GlaxoSmithKline "underweight" - JP Morgan Securities - 21 Oct 2008 Zudem stehe die nächste Phase bevor, in der GlaxoSmithKline die Folgen aus der Markteinführung von Nachahmerpräparaten (Lamictal, Imitrex, Paxil, Requip) zu Stock World, Neurogen: Positive Results for the Dopamine Agonist Aplindore - Oct 16, 2008 However, in RLS, aplindore's once-daily administration is equivalent to the current market leaders Mirapex and Requip, and the possibility of dosing RedOrbit, Parkinson's Disease Latest Update: Market upgrade following ... - Oct 6, 2008 GlaxoSmithKline's Requip XL (ropinirole extended-release) is set to become the market leading dopamine agonist in 2009. The convenience of once-daily dosing MarketWatch Denuncian tráfico con enfermedades - Oct 13, 2008 El ropirinol (Requip, de Glaxo) alivia el síndrome de las piernas inquietas, que afecta al 20% de la población, y el metilfenidato (Ritalina, de Novartis) El Nuevo Diario, There are a number of ways to fight restless legs - Sep 13, 2008 Mirapex and Requip are two newer ones. Sinemet is another popular prescription. All three are Parkinson's medicines, but restless leg syndrome is not SouthCoastToday.com, Focus on the World Alzheimer's and Parkinson's Disease Market - Sep 15, 2008 II-30 Levodopa/Carbidopa II-30 Dopamine Agonists II-30 Pergolide/Permax II-30 Bromocriptine/Parlodel II-30 Ropinirole/Requip II-30 Pramipexole/Mirapex MarketWatch Forecast Insight: Parkinson's Disease - Market upgrade following ... - Sep 5, 2008 GlaxoSmithKline's Requip XL (ropinirole extended-release) is set to become the market leading dopamine agonist in 2009. The convenience of once-daily dosing Pharmaceutical Business Review Pharmacy Offers Free Medication to Uninsured - Sep 4, 2008 ...take four to six weeks for the drugs to arrive, although the Med-Aid pharmacy keeps some popular drugs -- like Plavix, Zoloft and Requip -- in stock. MyFox WGHP, Learn about the World CNS Therapeutics Market - Sep 4, 2008 Anti-Parkinson's Drugs II-36 Levodopa II-36 Dopamine Agonists II-36 Mirapex II-36 Requip II-36 Anti-Epilepsy Drugs II-36 Carbamazepine II-36 Phenytoin MarketWatch Are you a real fidget in bed? This is how to cure restless legs - Sep 13, 2008 There are two licensed drugs available on prescription: Pramipexole (Miropexin) and Ropinirole (Requip). They work by activating the dopamine receptors and Daily Mail, 8 Sep, 2008, 0000 hrs IST,Rajrishi Singhal, ET Bureau - Sep 7, 2008 ...of its naming work includes Nexium (a gastrointestinal drug from AstraZeneca), Requip (a drug for combating Parkinson’s disease, from GlaxoSmitheKline). Economic Times, Iron deficiency can trigger restless legs syndrome - Aug 31, 2008 They include pramipexole (Mirapex) and ropinirole (Requip), which, most often, are first-line treatment options. Typically, evening doses of these Chicago Tribune, SkyePharma PLC -- Interim Results - Aug 27, 2008 ...agreement signed with Kyorin in Japan - Growth from approvals and launches of other products: - New Sular® formulation in USA - Requip® Once-a-day in CNNMoney.com Teva Tells It Like It Is - Aug 27, 2008 Bristol-Myers Squibb's (NYSE: BMY) Sinemet and with big-name drugs like GlaxoSmithKline's (NYSE: GSK) Requip, which also treats restless leg syndrome. Motley Fool Restless Legs: In Your Head Or In Your Genes? - Sep 4, 2008 TREATMENT: In 2005, the FDA approved the first drug to treat RLS -- ropinirole (Requip). The FDA then approved pramipexole (Mirapex) in 2006. WFtv.com, Will soap remedy help me sleep? - Sep 2, 2008 Requip no longer works, I get little sleep, and it is driving me nuts. A friend told me you had a soap remedy that might help me. I am counting on you! GoErie.com, Neurogen Corporation Q2 2008 Earnings Call Transcript - Sep 2, 2008 And we believe that this over-stimulation is largely responsible for the significant side effects observed with a full dopamine agonist such as Requip and Seeking Alpha, Stroke victim can't get a good sleep - Sep 3, 2008 Requip no longer works, I get little sleep, and it is driving me nuts. You are currently not logged into this site. Please log in or register for a FREE ONE Telegraph-Journal, Research and Markets: Out Now - CNS Drug Discoveries: Parkinson's ... - Sep 1, 2008 UCB -- Pardoprunox - Solvay -- Requip - GlaxoSmithKline For more information visit http://www.researchandmarkets.com/research/9a0ef4/cns_drug_discoveri. StreetInsider.com (subscription), Brand Names/Synonyms: Requip is also known by the following brand names and/or synonymsCHEMBANK1792; Requip; Ropinirol [Inn-Spanish]; Ropinirole; Ropinirole Hcl; Ropinirole Hydrochloride; Ropinirolum [Inn-Latin] Drug Category: Requip is categorized under the following by the FDA: Dopamine Agonists; Antiparkinson Agents; Antidyskinetics; Central Nervous System Agents; ATC:N04BC04 Dosage Forms: TABLET (0.25 mg, 0.5 mg, 1 mg, 2 mg, 4 mg or 5 mg) Absorption: Absolute bioavailability is 55%, indicating a first pass effect. Food does not affect the extent of absorption. Interactions: Interactions for Ropinirole: P 450 Interaction: In vitro metabolism studies showed that CYP1A2 was the major enzyme responsible for the metabolism of ropinirole. There is thus the potential for substrates or inhibitors of this enzyme when coadministered with ropinirole to alter its clearance. Therefore, if therapy with a drug known to be a potent inhibitor of CYP1A2 is stopped or started during treatment with Requip , adjustment of the Requip dose may be required. L-dopa: Co-administration of carbidopa + L-dopa (Sinemet® 10/100 mg b.i.d.) with ropinirole (2.0 mg t.i.d.) had no effect on the steady-state pharmacokinetics of ropinirole (n=28 patients). Oral administration of Requip 2.0 mg t.i.d. increased mean steady state C max of L-dopa by 20% but its AUC was unaffected (n=23 patients). Digoxin: Co-administration of Requip (2.0 mg t.i.d.) with digoxin (0.125-0.25 mg q.d.) did not alter the steady-state pharmacokinetics of digoxin in 10 patients. Theophylline: Administration of theophylline (300 mg b.i.d., a substrate of CYP1A2) did not alter the steady-state pharmacokinetics of ropinirole (2 mg t.i.d.) in 12 patients with Parkinson's disease. Ropinirole (2 mg t.i.d.) did not alter the pharmacokinetics of theophylline (5 mg/kg i.v.) in 12 patients with Parkinson's disease. Ciprofloxacin: Co-administration of ciprofloxacin (500 mg b.i.d.), an inhibitor of CYP1A2, with ropinirole (2 mg t.i.d.) increased ropinirole AUC by 84% on average, and C max by 60% (n=12 patients). Estrogens: Population pharmacokinetic analysis revealed that estrogens (mainly ethinylestradiol: intake 0.6-3 mg over 4-month to 23-year period) reduced the oral clearance of ropinirole by 36% in 16 patients. Dosage adjustment may not be needed for Requip in patients on estrogen therapy because patients must be carefully titrated with ropinirole to tolerance or adequate effect. However, if estrogen therapy is stopped or started during treatment with Requip , then adjustment of the Requip (ropinirole hydrochloride) dose may be required. Dopamine Antagonists: Since ropinirole is a dopamine agonist, it is possible that dopamine antagonists, such as neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of Requip . Patients with major psychotic disorders, treated with neuroleptics, should only be treated with dopamine agonists if the potential benefits outweigh the risks. Population analysis showed that commonly administered drugs, e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, and anticholinergics did not affect the oral clearance of ropinirole. Chemical IUPAC Name: 4-(2-dipropylaminoethyl)-1,3-dihydroindol-2-one : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |